Biogen Idec   2Q Revenues: $1.4 billion (+18%)   2Q Earnings: $387.1 million (+27%)   YTD Revenues: $2.7 billion (+12%)   YTD Earnings: $689.5 million (+13%)   Comments: Global in-market sales of TYSABRI in the quarter were $395 million (+2%). Revenues from other products were $34 million, compared to $16 million in 2Q11. Royalty revenues were $37 million, up 29%. AVONEX revenues increased 16% to $762 million. RITUXAN revenues from Biogen’s joint business arrangement were $285 million, up 31%, b...